Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
Type:
Application
Filed:
March 13, 2008
Publication date:
October 29, 2009
Applicant:
ZymoGenetics, Inc.
Inventors:
Paul O. Sheppard, Theresa A. Deisher, Paul D. Bishop, Stephen R. Jaspers, Virender M. Labroo
Abstract: Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 18, 2006
Date of Patent:
October 27, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
October 27, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Abstract: Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.
Type:
Grant
Filed:
June 22, 2007
Date of Patent:
October 27, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Jane A. Gross, Wenfeng Xu, Randal M. Henne, Francis J. Grant
Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
October 27, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Scott R. Presnell, Theodore E. Whitmore, Francis J. Grant, Emily C. Costerison
Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
October 13, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Scott R. Presnell, Wenfeng Xu, Julia E. Novak, Theodore E. Whitmore, Francis J. Grant
Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
Type:
Grant
Filed:
April 29, 2008
Date of Patent:
October 13, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
Type:
Application
Filed:
March 2, 2009
Publication date:
October 8, 2009
Applicant:
ZymoGenetics, Inc.
Inventors:
Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
Abstract: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of a zvegf3 protein in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of osteoblasts, osteoclasts, chondrocytes, or bone marrow stem cells comprising culturing the cells in an effective amount of a zvegf3 protein.
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
September 29, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Abstract: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
Type:
Grant
Filed:
October 12, 2006
Date of Patent:
September 22, 2009
Assignee:
Zymogenetics, Inc.
Inventors:
Penny J. Thompson, Katherine E. Lewis, Richard M. Garcia, Robert R. West, Paul O. Sheppard
Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
Type:
Grant
Filed:
October 20, 2006
Date of Patent:
September 22, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
Type:
Grant
Filed:
November 28, 2006
Date of Patent:
September 22, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Pallavur V. Sivakumar, Stephen R. Jaspers
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
September 15, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
September 15, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
Type:
Grant
Filed:
July 18, 2006
Date of Patent:
September 8, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
September 1, 2009
Assignee:
ZymoGenetics, LLC
Inventors:
Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski